Please see below a list of publications arising from some of the scintigraphy studies we have conducted (2000 - 2017). We are able to provide re-prints of some of the articles, please contact us for futher information.

Blanchard JD, Cipolla D, Liu K, Morishige R, Mudumba S, Thipphawong J, Taylor G, Warren S, Radhakrishnan R, Van Vlasselaer R, Visor G, Starko K.  Lung Deposition of Interferon Gamma-1ß following Inhalation via AERx® System vs. Respirgard II Nebulizer.  Am J Respir Crit Care Med 2003; 168: A373.

Boyd B, Liu K, Okikawa, J, Noymer, P, Hasegawa, D, Warren S, Taylor G, Ferguson, E, Farr S, Gonda I.  The Effect of Different Mouthpiece Shapes on Bolus Aerosol Delivery in Males and Females using the AERx® Pulmonary Delivery System.  Proc Drug Del Lungs 2000; 11: 86-89.

Boyd B, Noymer P, Liu K, Okikawa J, Hasegawa D, Warren SJ, Taylor G, Ferguson E, Schuster J, Farr SJ, Gonda I. Effect of Gender and Device Mouthpiece Shape on Bolus Insulin Aerosol Delivery Using the AERx Pulmonary Delivery System.  Pharm Res 2004; 21: 1776-1782. https://doi.org/10.1023/B:PHAM.0000045228.32419.ba

Cipolla D, Boyd, B, Evans R, Warren S.J, Taylor G, Farr SJ. Bolus Administration of High Dose Drugs: Studies using the AERx® Pulmonary Delivery System to Deliver INS365.  Proc Respir Drug Del 2000; 7: 231-239.

Cipolla D, Bruinenberg, P, Gonda I, Morishige, R, Taylor G, Warren S, von Kessler KRB, Otulana, B, Sullivan, EJ. Deeper Lung Pulmonary Delivery of Treprostinil is Associated with Delayed Systemic Absorption.  J Aerosol Med Pulm Drug Del 2011; 24: A44. poster available at http://files.shareholder.com/downloads/ARDM/0x0x881178/424DDA41-4161-4930-B41F-A1211A2B2D4B/Deeper_Lung_Pulmonary_Delivery_of_Treprostinil_is_Associated_with_Delayed_Systemic_Absorption.pdf

Devadason SG, Chan HK, Haeussermann S, Kietzig C, Kuehl PJ, Newman S, Sommerer K, Taylor G. Validation of Radiolabeling of Drug Formulations for Aerosol Deposition Assessment of Orally Inhaled Products. J Aerosol Med Pulm Drug Del 2012; 25, S1: S6-S9. https://doi.org/10.1089/jamp.2012.1Su3

Dickinson PA, Seville PC, McHale H, Perkins NC, Taylor G.  An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants. J Aerosol Med 2000; 13: 179-186. https://doi.org/10.1089/jam.2000.13.179

Evans R, Johnson, F, Kaufman, B, Kellerman, D, Boyd, B, Cipolla D, Farr S, Taylor G, Warren S, Ferguson E. High Lung Doses of a Novel Therapeutic Agent Achieved using a Novel Delivery System. Proc Drug Del Lungs 2000; 11: 78-81.

Evans R, Johnson, F, Kellerman, D, Boyd, B, Cipolla D, Farr SJ, Taylor G, Warren SJ. Aerosolised INS365 for COPD: Enhanced Deposition and Clearance Using the AERx Delivery System. Am J Respir Crit Care Med 2000; 161: A815.

Evans R, Kaufman, B, Kellerman, D, Boyd, B, Farr S, Taylor G, Warren S. Characterization of the In-Vitro and In-Vivo Performance of Two Popular Air-Jet Nebulizers. J Allergy Clin Immunol 2001; 107: S829.

Hampson F, Jolliffe, I, Bakhtyari A, Taylor G, Sykes J, Johnstone L, Dettmar P. Alginate-Antacid Combinations: Raft Formation and Gastric Retention Studies. Drug Dev Ind Pharm 2010; 36: 614-623.  https://doi.org/10.3109/03639040903388290

Farr SJ, Warren SJ, Lloyd P, Okikawa J, Schuster JA, Rowe AM, Rubsamen RM, Taylor G. Comparison of in Vitro and in Vivo Efficiencies of a Novel Unit-Dose Liquid Aerosol Generator and a Pressurized Metered Dose Inhaler. Int J Pharm 2000; 198: 63-70.

Gonda I, Cousins M, Farr SJ, Lloyd P, Lloyd J, Mather L, Okikawa J, Rubsamen R, Schuster JA, Taylor G, Ward E, Warren SJ. Microprocessor-Assisted Lung Delivery: Control of Compliance for Optimum Local and Systemic Delivery. Proc Control Rel Soc 1996; 23: 849-850.

Gumbleton M, Taylor G. Challenges and Innovations in Effective Pulmonary Systemic and Macromolecular Drug Delivery.  Adv Drug Del Rev 2006; 58: 993-995.   https://doi.org/10.1016/j.addr.2006.07.011

Jones R, Evans R, Warren S, Taylor G.  Development of a Novel Suspension MDI Formulation Using a Low Energy Dispersion System. Proc Respir Drug Del 2002; 8: 799-802.

Jones R, Evans R, Warren S, Taylor G.  Development of a Fluticasone Suspension pMDI Formulation Using a Second Particulate System. Proc Respir Drug Del 2004; 9: 401-404.

Kellerman D, Kori S, Forst A, Chang J, Febbraro S, WuTann L,  Thomas T, Taylor G, Dodick DW. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalagia 2012; 32: 150-158. https://doi.org/10.1177/0333102411432299

Kellerman D, Warren S, Rossi A, Taylor G, Smiley L. Deposition and pharmacokinetic studies with inhaled P2Y2 agonists – evidence of high lung delivery and minimal systemic exposure. J Cystic Fibrosis 2007; 6, S1, S11. https://doi.org/10.1016/S1569-1993(07)60039-3

Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, Fleming J, Haeussermann S, Kietzig C, Kuehl PJ, Laube BL, Sommerer K, Taylor G, Usmani OS, Zeman KL. Standardization of Techniques for Using Planar (2D) Imaging for Aerosol Deposition Assessment of Orally Inhaled Products. J Aerosol Med Pulm Drug Del 2012; 25, S1: S10-S28.  https://doi.org/10.1089/jamp.2012.1Su4

Nikander K, Prince IR, Coughlin SR, Warren S, Taylor G.  Lung Deposition of 99mTc-DTPA Delivered with the I-Neb® Adaptive Aerosol Delivery (AAD®) System. J Aerosol Med 2007; 20: 192-193.

Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of Breathing – Tidal or Slow and Deep – Through the I-Neb Adaptive Aerosol Delivery (AAD) System Affects Lung Deposition of 99mTc-DTPA. J Aerosol Med Pulm Drug Del 2010; 23, S1: S37-S43. https://doi.org/10.1089/jamp.2009.0786

Sanders M, Tran C. Technique improvement for a combination aerosol inhaler. Abs ISAM Conference 2017; P115. https://doi.org/10.1089/jamp.2017.ab01.abstracts

Sanders M, Bruin R, Tran C. Sealed Lips Instruction for Pressurised Metered Dose Inhalers (pMDIs) - A Critical Step? Eur Resp J 2014; 44,S58: P3025. Available from http://erj.ersjournals.com/content/44/Suppl_58/P3025

Sanders M, Bruin R, Tran C. Design and Development of a New pMDI Training Aid. Thorax 2015; 70, S3: A241. https://doi.org/10.1136/thoraxjnl-2015-207770.459

Sanders M, Bruin R, Tran C. Improving the Valved Holding Chamber (VHC)-Pressurised Metered Dose Inhaler (pMDI) Combination. J Aerosol Med Pulm Drug Del 2015; 28(3): P-136. https://doi.org/10.1089/jamp.2015.ab01.abstracts

Sanders M, Bruin R, Tran C. Overcoming Differences in pMDI Resistance to Create a Standardised Training Tool. Proc Drug Del Lungs 2015; 26: 346-349.  Available from https://aerosol-soc.com/abstracts/overcoming-differences-pmdi-actuator-resistance-create-standardised-training-tool/

Sanders M, Bruin R, Tran C. Development of a Whistling Facemask for Young Children. Prim Care Resp Med 2016; 26: 16077 A35.

Sanders M, Bruin R, Tran C. Use and Misuse: Salbutamol Through an Emergency Spacer Device. Prim Care Resp Med 2016; 26: 16077 A36.

Sanders M, Bruin R, Tran C.  Fungal Contamination of Valved Holding Chambers (VHCS): Potential to Prevent, and Effect on Drug Delivery. Thorax 2016; 71, S3: P129. http://dx.doi.org/10.1136/thoraxjnl-2016-209333.272

Sanders M, Bruin R, Tran C.  Aspergillus Fumigatus in Valved Holding Chambers: Use of Silver-Ion Additive Technology on Fungal Activity and Aerosol Delivery Characteristics.  Proc Drug Del Lungs 2016; 27: 78-81.

Sanders M, Bruin R, Tran C. Holding Chamber Valve Technology: Effectiveness at Low Flow Rates. Abs ISAM Conference 2017; P87. https://doi.org/10.1089/jamp.2017.ab01.abstracts

Sanders M, Bruin R, Tran C. Development of a Non-Electronic Technique-Based ‘Smart’ Inhaler. Abs ISAM Conference 2017; P88. https://doi.org/10.1089/jamp.2017.ab01.abstracts

Sanders M, Bruin R, Tran C, Warren S. Emergency Room Use of Valved Holding Chambers (VHCs) — Can it be Improved? Eur Respir J  2014; 44, S58: P4902. Available from http://erj.ersjournals.com/content/44/Suppl_58/P4902.article-info

Scheuch G, Bennett W, Borgstrom L, Clark A, Dalby R, Dolovich M, Fleming J, Gehr P, Gonda I, O'Callaghan C, Taylor G, Newman S. Deposition, Imaging, and Clearance: What Remains to be Done? J Aerosol Medicine Pulm Drug Del 2010; 23, S2: S39-S57. https://doi.org/10.1089/jamp.2010.0839

Shrewsbury SB, Cook R, Taylor G, Edwards C, Ramadan N. Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel System (Tempo(TM) Inhaler). Headache 2007; 47: 753-754.  https://doi.org/10.1111/j.1526-4610.2007.01006.x

Shrewsbury SB, Cook R, Taylor G, Edwards C, Ramadan N. Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo (TM) Inhaler). J Aerosol Med 2007; 20: 172.

Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered via a Novel (Tempo(TM)) Inhaler. Headache 2008; 48: 355-367. https://doi.org/10.1111/j.1526-4610.2007.01006.x

Taylor G. The Highs and Lows of Pharmacokinetics in Determining the Equivalence of Inhaled Medicinal Products. Proc Drug Del Lungs 2010; 21: 6-9.

Taylor G. Distilling Key Information on the Efficacy of Pulmonary Drug Delivery from PK and PD Studies. Proc Drug Del Lungs 2013; 24: 8-11.

Taylor G, Gumbleton M. Aerosols for macromolecular delivery: Design challenges and solutions. Am J Drug Del 2004; 2: 143-155. https://doi.org/10.2165/00137696-200402030-00001

Taylor G, Warren SJ. Methods for Tissue Attenuation Correction in Inhalation Pharmaceutical Scintigraphy Studies. Proc Respir Drug Del 2010; 12: 112-116.

Taylor G, Howard A, Jones R, Evans R. Amino Acids as Secondary Particulate Excipients in pMDI’s. AAPS PharmSci 2003; 5, S1: T3254.

Taylor G, Thomas I, Warren SJ, Kellerman D, Momose D. Gamma Scintigraphic Evaluation of INS365 Deposition Following JetHaler DPI Administration. J Aerosol Med 2007; 20: 193.

Taylor G, Tran CH, Warren SJ, Thomas I, Marchetti G. The Kemp HFA pMDI Valve for Delivery of Novel Budesonide/Formoterol Fumarate Combination Formulations. Proc Respir Drug Del 2008; 11: 983-986.

Taylor G, Tran CH, Zheng C, Warren S. In Vitro Comparison of Tiotropium Deposition from Novel pMDI Formulations, Spiriva® Handihaler® and Respimat® Soft Mist™ Inhaler. Proc Respir Drug Del 2014; 14: 433-438.

Taylor G, Tran CH, Zheng C, Warren SJ. Application of an Opt2FillTM Dispersible Tablet to the Production of a Novel Salmeterol/Fluticasone pMDI. Proc Respir Drug Del 2016; 15: 381-384.

Taylor G, Warren S.J, McRae, D, Venitz, J. Human Deposition and Exposure Studies with Propylene Glycol Aerosols Produced Using the CAG Technology Platform. Proc Respir Drug Del 2006; 10: 183-190.

Taylor G, Warren S, Orevillo C., Maes A, Martin UJ, Dwivedi S, Reisner C.  Pulmonary deposition of a novel LAMA/LABA Co-Suspension ™ Technology Glycopyrronium/Formoterol (GFF) MDI in Healthy Subjects (PT003020).  Eur Respir J  2016; 48, S60: OA4834. Available from http://erj.ersjournals.com/content/48/suppl_60/OA4834.

Taylor G, Warren S, Tran CH. Pressurised Metered Dose Inhalers and Method of Manufacture. WO2015121653 (A1).

Taylor G, Warren SJ, Tran CH. Next Generation Formulations for pMDIs. Proc Drug Del Lungs 2016; 27: 65-68.   Slides available from https://aerosol-soc.com/assets/uploads/2016/06/1630-Taylor-Pent-Thurs.pdf and abstract from https://aerosol-soc.com/abstracts/next-generation-formulations-pmdis/

Tran C, Bray H, Evans R, Taylor G. The Effects of Excipient Surface Interactions on Aerosol Performance of Pressurised Meter Dose Inhalers. J Pharm Pharmacol 2005; 57: S21.

Tran CH, Davies K, Medina AM, Warren S, Taylor G. An Evaluation of Formulation Variables on the Performance of an Innovative Budesonide pMDI Suspension. Proc Drug Del Lungs 2012; 23: 154-157.

Tran CH, Evans R, Taylor G. Analysis of Novel Pressurised Metered Dose Inhaler (pMDI) Formoterol Fumarate Formulations. Proc Drug Del Lungs 2005; 15: 253-256.

Tran CH, Harries AB, Chi PLK, Evans R, Taylor G. Amino Acids as Excipients in Pressurised Metered Dose Inhaler Formulations. Proc Drug Del Lungs 2004; 15: 137-140.

Tran C, Harries A, Chi P, Evans R, Taylor G. Alternative Amino Acids as Potential Secondary Particulates in Pressurised Metered Dose Inhaler Formulations. Eur J Pharm Sci 2004; 23S: S63.

Tran CH, Medina AM, Davies K, Warren S, Marchetti G, Taylor G. Application of a Novel Platform Technology to the Formulation of a Salmeterol/Fluticasone pMDI. Proc Drug Del Lungs 2011; 22: 281-284.  Abstract available from https://doi.org/10.1089/jamp.2013.01ab

Tran CH, Zheng C, Warren S, Taylor G. Investigations of Tiotropium pMDI Suspension Formulations. Proc Drug Del Lungs 2013; 24, 122-125.    Abstract available from https://aerosol-soc.com/abstracts/investigations-tiotropium-pmdi-suspension-formulations/

Tran CH, Zheng C, Warren S, Taylor G. Opt2Fill™ Dispersible Tablet – A Novel Method for the Manufacture of pMDIs. Proc Drug Del Lungs 2016; 27 213-216.  Abstract available from https://aerosol-soc.com/abstracts/opt2filldispersible-tablet-novel-method-manufacture-pmdis/

Warren S, Taylor G. Morphometric Measures for Tissue Attenuation Corrections in Pharmaceutical Scintigraphy. AAPS PharmSci 2003; 5, S1: M1079.

Warren S, Taylor G. Quality Control Aspects of Pharmaceutical Gamma Scintigraphy Studies. Eur. Pharm. Contractor 2004; 1: 76-83.

Warren SJ, Taylor G, Smith J, Buck H, Parry-Billings M. Gamma Scintigraphic Evaluation of a Novel Budesonide Dry Powder Inhaler Using a Rigorously Validated Radiolabelling Technique. J. Aerosol Med. 2002; 15: 15-25. https://doi.org/10.1089/08942680252908548

Weers J, Metzheiser B, Perkins W, Meers P, Nicholson S, Taylor G, Warren S, Pilkiewicz F. A Pulmonary Sustained Release Formulation of Amikacin (SLIT™ Amikacin) for Pseudomonas Aeruginosa Infections in CF Patients. Am J Respir Crit Care Med 2005; 171: A64.

Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR.  A Gamma Scintigraphy Study to Investigate Lung Deposition and Clearance of Inhaled Amikacin-Loaded Liposomes in Healthy Male Volunteers. J Aerosol Med Pulm Drug Del 2009; 22: 131-138. https://doi.org/10.1089/jamp.2008.0693